Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Vyant Bio, Inc. | cgix-20161231x10xk.htm |
| EX-32.2 - EXHIBIT 32.2 - Vyant Bio, Inc. | a201610-kex322.htm |
| EX-32.1 - EXHIBIT 32.1 - Vyant Bio, Inc. | a201610-kex321.htm |
| EX-31.2 - EXHIBIT 31.2 - Vyant Bio, Inc. | a201610-kex312.htm |
| EX-31.1 - EXHIBIT 31.1 - Vyant Bio, Inc. | a201610-kex311.htm |
| EX-21.1 - EXHIBIT 21.1 - Vyant Bio, Inc. | a201610-kex211.htm |
| EX-10.84 - EXHIBIT 10.84 - Vyant Bio, Inc. | exh1084sitarrelease.htm |
| EX-10.83 - EXHIBIT 10.83 - Vyant Bio, Inc. | exh1083pfgwarrant.htm |
| EX-10.82 - EXHIBIT 10.82 - Vyant Bio, Inc. | exh1082pfgtermnote.htm |
| EX-10.81 - EXHIBIT 10.81 - Vyant Bio, Inc. | exh1081svbloan.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-191520, 333-191521, 333-196198, 333-205903 and 333-214599), on Form S-3 (No.333-196374) and on Form S-1 (No. 333-215284) of Cancer Genetics, Inc. of our report dated March 23, 2017, relating to the consolidated financial statements of Cancer Genetics, Inc. and Subsidiaries appearing in the Annual Report on Form 10-K of Cancer Genetics, Inc. for the year ended December 31, 2016.
/s/ RSM US LLP
New York, New York
March 23, 2017